Details of the Drug Reposition

General Information of This Drug (ID: DMHKCIS)

Drug Name
Aldoxorubicin   DMHKCIS
Synonyms
1361644-26-9; ALDOXORUBICIN; Doxorubicin-EMCH; 151038-96-9; Aldoxorubicin (USAN); CHEMBL2107818; SCHEMBL15221892; OBMJQRLIQQTJLR-LBMCFUDOSA-N; ZINC163337436; AKOS030526452; CS-1186; HY-16261; D10383; W-5595; (8S)-1-Methoxy-6,8alpha,11-trihydroxy-8-[1-[2-[6-(2,5-dioxo-3-pyrroline-1-yl)hexanoyl]hydrazono]-2-hydroxyethyl]-10alpha-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydronaphthacene-5,12-dione
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Soft tissue sarcoma DISSN8XB 2B57 Phase 3 [1]
------------------------------------------------------------------------------------
4 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glioblastoma multiforme DISK8246 2A00.0 Phase 2 [2]
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [3]
Pancreatic ductal carcinoma DIS26F9Q 2C10.0 Phase 2 [2]
Small-cell lung cancer DISK3LZD 2C25.Y Phase 2 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01580397) Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer. U.S. National Institutes of Health.